» Articles » PMID: 37403352

Radiotherapy Trend in Elderly Hepatocellular Carcinoma: Retrospective Analysis of Patients Diagnosed Between 2005 and 2017

Overview
Journal Radiat Oncol J
Specialty Oncology
Date 2023 Jul 5
PMID 37403352
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To report the trends of radiotherapy in the management of elderly patients with hepatocellular carcinoma (HCC).

Materials And Methods: We retrospectively reviewed patients who entered HCC registry of Samsung Medical Center between 2005 and 2017. Patients who were 75 years or older at the time of registration were defined as elderly. They were categorized into three groups based on the year of registration. Radiotherapy characteristics were compared between the groups to observe differences by age groups and period of registration.

Results: Out of 9,132 HCC registry patients, elderly comprised 6.2% (566 patients) of the registry, and the proportion increased throughout the study period (from 3.1% to 11.4%). Radiotherapy was administered to 107 patients (18.9%) in elderly group. Radiotherapy utilization in the early treatment process (within 1 year after registration) has rapidly increased from 6.1% to 15.3%. All treatments before 2008 were delivered with two-dimensional or three-dimensional conformal radiotherapy, while more than two-thirds of treatments after 2017 were delivered with advanced techniques such as intensity-modulated radiotherapy, stereotactic body radiotherapy, or proton beam therapy. Overall survival (OS) of elderly was significantly worse than younger patients. However, for patients who received radiotherapy during the initial management (within one month after registration), there was no statistically significant difference in OS between age groups.

Conclusion: The proportion of elderly HCC is increasing. Radiotherapy utilization and adoption of advanced radiotherapy technique showed a consistently increasing trend for the group of patients, indicating that the role of radiotherapy in the management of elderly HCC is expanding.

Citing Articles

Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer.

Byun H, Yoo G, Sung S, Song J, Kim B, Kwak Y Radiat Oncol J. 2025; 42(4):247-256.

PMID: 39748525 PMC: 11701464. DOI: 10.3857/roj.2024.00108.


Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage.

Saha B, Pallatt S, Banerjee A, Banerjee A, Pathak R, Pathak S Cells. 2024; 13(18.

PMID: 39329744 PMC: 11429644. DOI: 10.3390/cells13181560.


Has the growing evidence of radiotherapy for hepatocellular carcinoma increased the use of radiotherapy in elderly patients?.

Kim T Radiat Oncol J. 2023; 41(3):141-143.

PMID: 37793622 PMC: 10556838. DOI: 10.3857/roj.2023.00710.

References
1.
Marosi C, Koller M . Challenge of cancer in the elderly. ESMO Open. 2016; 1(3):e000020. PMC: 5070391. DOI: 10.1136/esmoopen-2015-000020. View

2.
Liu Y, Xue D, Tan S, Zhang Q, Yang X, Li Y . Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis. J Cancer. 2019; 10(17):4063-4071. PMC: 6692624. DOI: 10.7150/jca.29850. View

3.
Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H . Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res. 2019; 49(8):919-928. DOI: 10.1111/hepr.13348. View

4.
Pan C, Kavanagh B, Dawson L, Li X, Das S, Miften M . Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S94-100. PMC: 4388033. DOI: 10.1016/j.ijrobp.2009.06.092. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View